Medicare Enrolled
Dr. Maryjane Liebling, DO
Pulmonary Disease · Bradenton, FL
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Liebling from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Liebling?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Liebling
Dr. Maryjane Liebling is a pulmonary disease specialist in Bradenton, FL, with 18 years of NPI registration. Based on federal Medicare data, Dr. Liebling performed 2,409 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Liebling received a total of $6,916 from 33 pharmaceutical and/or device companies across 337 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Liebling is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 18 years of NPI registration
▲ Top 26% volume in FL
$6,916 industry payments
Florida License Status
FL DOH · MQA1
Active license
None
Board action on record
0
Recent admin complaints
| Profession | License # | Status | Expires | Board Action |
|---|---|---|---|---|
| Osteopathic Physician | 12582 | Clear | March 31, 2028 | — |
Data from Florida Department of Health Medical Quality Assurance.
License records are public under Chapter 119, Florida Statutes.
Verify directly on FL DOH →
Medicare Practice Summary — 2023
Medicare Utilization ↗2,409
Medicare services
Top 26% in FL for pulmonary disease
Not available
Unique patients (not deduplicated)
$70
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
696 | $94 | $125 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
200 | $123 | $163 |
| Lung volume test using gas dilution or washout A test that measures the amount of air in your lungs by using a gas dilution or washout method. |
168 | $33 | $41 |
| Hemoglobin a1c level, by device for home use | 167 | $10 | $10 |
| Pulmonary gas exchange test A test to examine how well the lungs exchange gases. |
167 | $42 | $54 |
| Office visit for established patient An office visit for an existing patient that may not require the healthcare professional to be present. |
167 | $17 | $22 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
164 | $61 | $87 |
| Spirometry test before and after medication A test that measures the amount of air you can exhale and the speed of your breathing before and after taking a medication. |
158 | $28 | $37 |
| Breathing device use evaluation An assessment of how a patient uses a breathing device. The provider reviews the patient's technique and device handling. |
106 | $12 | $16 |
| Critical care, first 30-74 min Emergency medical care for a critically ill or injured patient lasting between 30 and 74 minutes. This service involves direct patient care and medical decision making to stabilize the patient. |
83 | $171 | $710 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
78 | $100 | $139 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
62 | $137 | $554 |
| Exercise-induced lung stress test A test performed to evaluate how the lungs function during physical exertion. It helps identify breathing difficulties or lung conditions that occur specifically when exercising. |
53 | $26 | $33 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
45 | $135 | $174 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
44 | $94 | $234 |
| Lung cancer screening counseling visit A visit to discuss the need for lung cancer screening using a low-dose CT scan. This service is used to determine eligibility and facilitate shared decision making. |
27 | $27 | $28 |
| New patient office visit, complex (60-74 min) | 12 | $172 | $215 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
12 | $64 | $88 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
Industry Payment Transparency
Open Payments through 2024 ↗$6,916
Total received (2019-2024)
Avg $1,153/year across 6 years
Top 29% in FL for pulmonary disease
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
33
Companies
337
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,994
2023
$1,672
2022
$1,632
2021
$1,257
2020
$182
2019
$179
Payments by company (2024)
AstraZeneca Pharmaceuticals LP
$523
GlaxoSmithKline, LLC.
$349
Abbott Laboratories
$150
Regeneron Healthcare Solutions, Inc.
$144
Actelion Pharmaceuticals US, Inc.
$135
United Therapeutics Corporation
$118
Boehringer Ingelheim Pharmaceuticals, Inc.
$114
Insmed, Inc.
$114
GENZYME CORPORATION
$74
Paratek Pharmaceuticals, Inc.
$46
Bayer Healthcare Pharmaceuticals Inc.
$43
Merck Sharp & Dohme LLC
$41
Amgen Inc.
$33
Bard Peripheral Vascular, Inc.
$24
Grifols USA, LLC
$20
Electromed, Inc.
$19
Gilead Sciences, Inc.
$18
ABBVIE INC.
$16
INTUITIVE SURGICAL, INC.
$13
Top 3 companies account for 51.3% of 2024 payments
All-time payments by company (2019-2024) ›
AstraZeneca Pharmaceuticals LP
$1,302
GlaxoSmithKline, LLC.
$1,038
Actelion Pharmaceuticals US, Inc.
$903
Regeneron Healthcare Solutions, Inc.
$581
Boehringer Ingelheim Pharmaceuticals, Inc.
$534
Paratek Pharmaceuticals, Inc.
$334
Insmed, Inc.
$261
United Therapeutics Corporation
$228
Takeda Pharmaceuticals U.S.A., Inc.
$200
Bayer HealthCare Pharmaceuticals Inc.
$174
ZOLL Medical Corporation
$152
Abbott Laboratories
$150
Electromed, Inc.
$141
GENZYME CORPORATION
$112
Amgen Inc.
$98
Bayer Healthcare Pharmaceuticals Inc.
$97
Merck Sharp & Dohme LLC
$83
Mylan Specialty L.P.
$73
Grifols USA, LLC
$64
Vapotherm Inc
$55
Alexion Pharmaceuticals, Inc.
$44
JAZZ PHARMACEUTICALS INC.
$42
Fisher & Paykel Healthcare Inc
$39
Resmed Corp
$37
LivaNova USA, Inc.
$29
Bard Peripheral Vascular, Inc.
$24
Celgene Corporation
$22
Merck Sharp & Dohme Corporation
$21
Gilead Sciences, Inc.
$18
Boston Scientific Corporation
$16
ABBVIE INC.
$16
Mallinckrodt Hospital Products Inc.
$15
INTUITIVE SURGICAL, INC.
$13
Top 3 companies account for 46.9% of all-time payments
Associated products mentioned in payments ›
ACTHAR · AIR 11 · AIRCURVE · AIRSUPRA · ANDEXXA · ANORO ELLIPTA · AREXVY · AVYCAZ · Adempas · Arikayce · BREZTRI · DUPIXENT · Da Vinci Surgical System · FASENRA · FISHER & PAYKEL HEALTHCARE · GLASSIA · LifeSPARC System · MITRACLIP · NUCALA · NUZYRA · OFEV · OPSUMIT · ORENITRAM · Precision Flow · Prolastin-C Liquid · REBLOZYL · REMODULIN · RotarexS 6 F x 135 cm · SMARTVEST · STIOLTO RESPIMAT · SUNOSI · SYMBICORT · TEZSPIRE · TRELEGY ELLIPTA · TYVASO · UPTRAVI · Ultraflex Esophageal NG · VAPOTHERM · Veklury · WINREVAIR · YUPELRI · ZERBAXA
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Pulmonary diseases in nearby ZIP areas
36
County median income
$75,792
Nearest hospital to ZIP centroid (approximate)
SUNCOAST BEHAVIORAL HEALTH CENTER
4.2 mi
4.2 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Liebling is a clinical cardiology specialist, with above-average Medicare volume (top 26% in FL), with 18 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Liebling experienced with office visit, established patient (30-39 min)?
Based on Medicare claims data, Dr. Liebling performed 696 office visit, established patient (30-39 min) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Liebling receive payments from pharmaceutical companies?
Yes. Dr. Liebling received a total of $6,916 from 33 companies across 337 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Liebling's costs compare to other pulmonary diseases in Bradenton?
Dr. Liebling's average Medicare payment per service is $70. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Liebling) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Pulmonary Disease
Common procedures, typical costs, and what industry payments mean in pulmonary disease.
Same specialty & city
Pulmonary Diseases in Bradenton
Browse pulmonary diseases in Bradenton ranked by procedure volume and transparency data.
Highest volume
Top Pulmonary Diseases in FL
Pulmonary diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Pulmonary Diseases in FL
Which FL pulmonary diseases receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC.
By company
Actelion Pharmaceuticals US, Inc. Payments to Doctors
See all physicians who received payments from Actelion Pharmaceuticals US, Inc.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology